Shilpa Medicare Limited (SHILPAMED) — Announcement | 18 August 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Company initiates voluntary US recall of 27,923 Pemetrexed vials over discoloration.
💡 Investor Takeaway
The recall poses no material financial or operational risk to the company.

Shilpa Medicare Limited voluntarily recalled 27,923 vials of Pemetrexed Injection in the US due to discoloration, classified as a Class II FDA recall, but confirmed no adverse events and no material financial impact, maintaining transparency for investors.

📄 View Original Announcement (PDF)

About Shilpa Medicare Limited (SHILPAMED)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹17,391.14 Cr P/E: 48.2 ROE: 12.5% ROCE: 13.4% Div Yield: 0.07%

View full SHILPAMED stock details →

📡 Get AI alerts when SHILPAMED files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SHILPAMED — Free

📊 More SHILPAMED filings

See all SHILPAMED filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SHILPAMED files new disclosures

Track SHILPAMED filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SHILPAMED — Free

Free account · 2 AI queries/day